1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opioid Induced Bowel Dysfunction-Pipeline Insights, 2017


DelveInsight’s, “ Opioid Induced Bowel Dysfunction-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Opioid Induced Bowel Dysfunction. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Opioid Induced Bowel Dysfunction. DelveInsight’s Report also assesses the Opioid Induced Bowel Dysfunction therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Opioid Induced Bowel Dysfunction
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Opioid Induced Bowel Dysfunction pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Opioid Induced Bowel Dysfunction and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Opioid Induced Bowel Dysfunction-Pipeline Insights, 2017
Illustrative

- Opioid Induced Bowel Dysfunction Overview
- Opioid Induced Bowel Dysfunction Pipeline Therapeutics
- Opioid Induced Bowel Dysfunction Therapeutics under Development by Companies
- Opioid Induced Bowel Dysfunction Filed and Phase III Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Phase II Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Phase I and IND Filed Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Opioid Induced Bowel Dysfunction - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction - Discontinued Products
- Opioid Induced Bowel Dysfunction - Dormant Products
- Companies Involved in Therapeutics Development for Opioid Induced Bowel Dysfunction
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Opioid Induced Bowel Dysfunction, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Opioid Induced Bowel Dysfunction Assessment by Monotherapy Products
- Opioid Induced Bowel Dysfunction Assessment by Combination Products
- Opioid Induced Bowel Dysfunction Assessment by Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Stage and Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction Assessment by Stage and Molecule Type
- Opioid Induced Bowel Dysfunction Therapeutics - Discontinued Products
- Opioid Induced Bowel Dysfunction Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Opioid Induced Bowel Dysfunction, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Opioid Induced Bowel Dysfunction Assessment by Monotherapy Products
- Opioid Induced Bowel Dysfunction Assessment by Combination Products
- Opioid Induced Bowel Dysfunction Assessment by Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Stage and Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Emesis (Vomiting) Global Clinical Trials Review, H2, 2016

Emesis (Vomiting) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Emesis (Vomiting) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Emesis (Vomiting) Global Clinical Trials Review, H2, 2016" provides an overview of Emesis (Vomiting) ...

Joint Pain Global Clinical Trials Review, H2, 2016

Joint Pain Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Joint Pain Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Joint Pain Global Clinical Trials Review, H2, 2016" provides an overview of Joint Pain clinical trials ...

Dental Pain Global Clinical Trials Review, H2, 2016

Dental Pain Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Dental Pain Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Dental Pain Global Clinical Trials Review, H2, 2016" provides an overview of Dental Pain clinical trials ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • March 2017
    13 pages
  • Opioid  

  • United States  

View report >

Opioid Market in the US

  • March 2017
    11 pages
  • Opioid  

  • United States  

    Mexico  

View report >

Opioid Market in China

  • March 2017
    4 pages
  • Opioid  

  • China  

View report >

Related Market Segments :

Opioid

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.